Objective: Elevated ovarian hormone levels are associated with increased risk for binge eating (BE) and emotional eating (EE) during the midluteal phase of the menstrual cycle. However, past studies have not examined whether pronounced hormonal changes that precede the midluteal phase (i.e., the dramatic decrease in estradiol and increase in progesterone during/after ovulation) also influence midluteal increases in binge-related symptoms. Past theories and studies of phenotypes strongly related to BE (e.g., depression) suggest that these pronounced hormonal changes may also contribute. This study examined this possibility in 375 female twins (aged 15-25 years) from the Michigan State University Twin Registry.
| INTRODUCTION
Fluctuations in ovarian hormones increase risk for binge eating (BE) and emotional eating (EE), with the greatest risk occurring during the midluteal phase of the menstrual cycle when ovarian hormones are elevated (Edler, Lipson, & Keel, 2007; Klump et al., 2013 Klump et al., , 2014 .
The antagonistic relationship between estrogen and progesterone is thought to underlie this observation. In the absence of progesterone, estrogen decreases food intake (Asarian & Geary, 2013) , BE, and EE (Micioni Di Bonaventura et al., 2017) . However, when present, progesterone inhibits estrogen's protective benefits and increases BE and EE levels (Klump et al., , 2014 .
Past studies showing these associations have focused on whether morning levels of a woman's hormones, relative to her mean hormone levels, predicted EE later that day. While these analyses significantly increased understanding of daily changes in hormones/ EE, some suggest that pronounced hormonal changes (e.g., maximumminimum hormone levels) may also predict BE phenotypes (Edler et al., 2007) . If so, then perhaps women with the most pronounced ovulatory changes in ovarian hormones may be at the greatest risk of BE and EE. Ovulation is the period of maximal hormonal change during the menstrual cycle, with estradiol levels dramatically increasing then decreasing during ovulation, and progesterone levels increasing after ovulation. Given that peak rates of BE and EE occur after ovulation, pronounced changes in ovarian hormone levels during/ after ovulation may also contribute to the increased risk for bingerelated eating. Animal studies show that effects of hormones on behavior typically take up to 24-48+ hr to occur (Geary & Asarian, 1999; Gray & Greenwood, 1982) . Because ovulation occurs approximately 3-8 days before the midluteal phase (Ecochard et al., 2017) , pronounced ovulatory hormonal shifts may also contribute to increased BE and EE in women. While no study has examined these types of effects, studies show associations between pronounced hormonal changes and other phenotypes linked to BE (e.g., depression ; Freeman, 2010; Freeman et al., 2007; Schmidt & Rubinow, 2009 ).
This study examined whether pronounced hormonal changes during/after ovulation predicted increased EE during the midluteal phase in a population-based sample of women.
| METHOD

| Participants
Participants included 445 female twins (15-25 years old) from the Twin Study of Hormones and Behavior Across the Menstrual Cycle (TSHMBC; Klump et al., 2013) within the Michigan State University Twin Registry (MSUTR; see Klump & Burt, 2006 for MSUTR description) . This same sample participated in our previous reports (e.g., Klump et al., 2013 Klump et al., , 2014 showing associations between hormone levels and EE/BE. Twins had to meet several inclusion criteria for the TSHMBC study (e.g., no medication usesee Klump et al., 2014) . Additionally, for the current study, cycles were required to demonstrate a peak in estradiol during ovulation, resulting in a final sample of 375 women (84%; 375/445). Participants remained demographically representative of the recruitment region (see Supporting Information Table S1 and Klump et al., 2013) .
Participants were mostly of Non-Hispanic descent (92%), with 84% identifying as White, 10% Black, 5% Multiracial, 0.5% Native American, and 0.3% Asian or Pacific Islander.
| Procedures
All measures and procedures were approved by the Michigan State University Institutional Review Board. Participants provided behavioral and hormone data for 45 consecutive days. Salivary samples were collected within 30 min of waking using previously established methods (Edler et al., 2007; Klump et al., 2013; Klump, Keel, Culbert, & Edler, 2008) and assayed for ovarian hormones by Salimetrics, LLC using enzyme immunoassays that show excellent intra-and interassay coefficients of variation (see Klump et al., 2013) . Participants recorded days of menstrual bleeding in a daily log book. Trained raters coded cycle phase using information about each twin's cycle length and the hormone data (see Klump et al., 2015 for method description). (Wardle, 1987) and is correlated with measures of BE (r's = .55-.69; Racine, Culbert, Larson, & Klump, 2009; van Strien, 2000) and palatable food intake in the laboratory (van Strien, 2000) . Similar to previous research (Klump et al., 2008) , the DEBQ instructions were modified with permission to ask about EE over the current day.
| Measures
The negative affect scale from the positive and negative affect schedule (Watson, Clark, & Tellegen, 1988 ) assessed participants' daily negative affect. The negative affect scale exhibits excellent internal consistency and good convergent and discriminant validity (Watson et al., 1988) . Internal consistency in the current study was excellent (45-day average α = 0.85).
Height and weight were measured using a wall-mounted ruler and digital scale during three in-person visits (i.e., beginning, halfway point, and end of study). Mean body mass index (BMI) (weight [kg]/height [m] 2 ) was calculated and used in analyses.
| Statistical analyses and models
Data preparation followed methods from previous studies (Edler et al., 2007; Klump et al., 2008 Klump et al., , 2013 . For the repeated measures (i.e., EE, hormones, negative affect), 5-day rolling averages were calculated by anchoring each day as Day 0 and including the 2 days on either side.
Rolling averages were then converted to within-person, standardized scores based upon each participant's mean/standard deviation across data collection (see Lester, Keel, & Lipson, 2003) .
EE scores in the midluteal phase were used as the outcome variables in all analyses. Within-person hormonal change was the predictor variable and was assessed using each women's individual hormone difference score across ovulation for estrogen (i.e., maximum during ovulation − minimum in transition to midluteal), and across the midluteal phase for progesterone (i.e., maximum during the midluteal phase − minimum levels during the transition to midluteal phase). Negative affect difference scores (calculated in the same manner as above) and BMI were included as covariates in analyses.
Data were restricted to one complete cycle from the 45-day period.
Pearson correlations provided initial indications of associations between pronounced hormone changes and EE scores. Mixed linear models (MLMs) were then used to examine how the hormone difference scores predicted average EE scores in the midluteal phase.
MLMs have been used in past work (see Klump et al., 2013 Klump et al., , 2014 and are well suited for these analyses because they examine predictive associations while controlling for covariates (i.e., negative affect, BMI) and nonindependence of twin data. Separate models were run for the maximum/minimum scores and the difference scores due to high multicollinearity between the difference scores and maximum/ minimum scores. All MLMs were conducted for estrogen only, progesterone only, and then a set of joint hormone models to examine potential estrogen × progesterone interactions.
| RESULTS
Results showed ample variability in the range of EE (raw score range = 0-4.01, within-person z-score range = −1.39 to 1.71) and hormone scores (i.e., 0.03-4.46; see Supporting Information Table S1 ).
Pearson correlations showed no significant associations between EE scores in the midluteal phase and any of the maximum/minimum hormone values or difference scores (r's = .001-.10; p's > .10; see Table 1 ).
Likewise, no significant main effects of maximum/minimum hormone levels, difference scores, or significant interactions were found in the MLMs for either estrogen or progesterone alone or in the joint hormone models (all p's > .05, see Table 2 ).
Because effects were counter to hypotheses, post hoc analyses were conducted to ensure that results were not unduly influenced by study design decisions or missing data. To ensure that results were not due to the exclusion of participants missing the transition to midluteal phase (see Section 2), models were rerun using maximum, minimum, and difference scores from other phases around ovulation (i.e., ovulation to the midluteal phase, rather than the transition to midluteal phase; follicular phase to ovulation). Again, no significant main or interaction effects were observed (all p's > .05; see Supporting Information Table S2 ). Nonetheless, it is possible that our 5-day rolling averages over-or underestimated mean hormone levels across phases, given varying phase lengths. All models were rerun using single day maximum/minimum values and 2-and 3-day rolling averages.
Still, no significant associations were found (all p's > .05; see Supporting Information Table S3 ).
Although past work showed similar hormone/EE associations in clinical versus nonclinical samples (Edler et al., 2007; Klump et al., 2008 Klump et al., , 2014 , effects of pronounced hormonal change may only be present in women with more severe levels of pathology. Exploratory analyses examined women (n = 20) who endorsed a lifetime history of BEs (i.e., episodes defined by a large amount of food and a loss of control) on diagnostic interviews (see Klump et al., 2014 for methods).
Results remained unchanged (all p's > .05; see Supporting Information Table S4 ). Finally, it is possible that pronounced hormonal change/EE associations are only present in women with extreme hormonal changes. We compared EE scores between women whose hormone difference scores fell in the top versus bottom third of the distribu- although pronounced changes in estradiol and progesterone are expected components of the menstrual cycle that trigger and follow ovulation, ovulation may not increase EE risk. Conversely, large deviations from mean hormone levels in the midluteal phase (examined in previous studies) may reflect a riskier hormonal milieu for women because they coincide with the period in which conception may occur during which greater food intake would be desirable.
Despite the strengths of our study (e.g., large sample size, intensive daily data), limitations should be noted. A subsample of participants (8%) was eliminated from the primary analyses due to an inability to confirm ovulation. While this may have affected results, post hoc analyses including these participants yielded similar results (see Supporting Information Table S2 ). We used a community, not clinical, sample of women. Past studies suggest no significant differences in effects across clinical and community samples (Edler et al., 2007; Klump et al., 2008 Klump et al., , 2013 , and post hoc analyses suggested similar findings in women with
BEs. Nevertheless, our BE group was small (n = 20), suggesting a need for larger-scale studies to replicate our results.
We relied on difference scores for measuring hormonal changes.
Difference scores are limited by increased measurement error (Bereiter, 1963) 
